Sclerosis: all 3,103 studies

Page 26 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.

• Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple SclerosisStatus unknownNCT01576354Phase 2
• Examining the Effects of a Telehealth Self-management Intervention in Multiple SclerosisCompletedNCT01572714Not applicable
• Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral SclerosisStatus unknownNCT01569958Phase 2
• The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.TerminatedNCT01567553
• Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)WithdrawnNCT01565395Phase 2
• Effects of Electromechanical Gait Trainer in Patients With Multiple SclerosisCompletedNCT01564511Not applicable
• Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)WithdrawnNCT01563900Not applicable
• Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis PatientsWithdrawnNCT01555684Not applicable
• Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related SialorrheaCompletedNCT01551940Phase 2
• Assessing Relapse in Multiple Sclerosis (ARMS) QuestionnaireCompletedNCT01547351
• Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple SclerosisCompletedNCT01547234
• A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple SclerosisCompletedNCT01541618
• A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple SclerosisWithdrawnNCT01539395
• A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple SclerosisCompletedNCT01538355Not applicable
• Neurophysiological Study of Sativex in Multiple Sclerosis (MS) SpasticityCompletedNCT01538225Phase 3
• Self Help for Fatigue in Multiple SclerosisCompletedNCT01532037Not applicable
• Study of Cognitive and Emotional Disorders in Amyotrophic Lateral SclerosisStatus unknownNCT01530438Not applicable
• Multiple Sclerosis and Progressive Resistance TrainingCompletedNCT01518660Not applicable
• Oral Testosterone for Fatigue in Male Multiple Sclerosis PatientsTerminatedNCT01516554Phase 2
• Pacing Activity Self-management for Patients With Multiple SclerosisCompletedNCT01512329Phase 2
• Occupational Therapy in Patients With Multiple SclerosisCompletedNCT01507636Not applicable
• Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01504009Not applicable
• A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) BiomarkersCompletedNCT01495390
• The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral SclerosisStatus unknownNCT01494480Phase 2
• The Effects of Attention Retraining in MSCompletedNCT01492023
• Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple SclerosisCompletedNCT01491100
• Canadian Avonex PEN Productivity StudyCompletedNCT01489748
• Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic SclerosisCompletedNCT01488214Not applicable
• Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT01487096Phase 2
• Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01486849Phase 2
• Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsCompletedNCT01485003
• Worms for Immune Regulation of Multiple SclerosisCompletedNCT01470521Phase 2
• Hemodynamic Changes in Connective Tissue DiseaseCompletedNCT01468792
• A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.CompletedNCT01466322Phase 1
• Estriol Treatment in Multiple Sclerosis (MS): Effect on CognitionStatus unknownNCT01466114Phase 2
• Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Status unknownNCT01464905Phase 3
• Task-oriented Circuit Class Training in Multiple Sclerosis SubjectsCompletedNCT01464749Not applicable
• Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular DisordersWithdrawnNCT01459302
• Glatiramer Acetate for Multiple Sclerosis With Autoimmune ComorbiditiesCompletedNCT01456416
• The Effects of Aerobics Training on Balance in Patients With Multiple SclerosisStatus unknownNCT01453868Early Phase 1
• Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisWithdrawnNCT01453764Not applicable
• Neuroprotection With Phenytoin in Optic NeuritisCompletedNCT01451593Phase 2
• Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisCompletedNCT01450488Phase 2
• Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)CompletedNCT01450124Phase 2
• T Cell Vaccination in Patients With Progressive Multiple SclerosisCompletedNCT01448252Phase 1/2
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying TherapiesCompletedNCT01442194
• Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)TerminatedNCT01440062Phase 2
• Low Protein Diet in Patients With Collagen VI Related MyopathiesCompletedNCT01438788Phase 2
• China Betaferon Adherence, Coping and Nurse Support StudyCompletedNCT01436838
• Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple SclerosisTerminatedNCT01435993Phase 1
• Robot-assisted Gait Training in Multiple Sclerosis SubjectsCompletedNCT01435694Not applicable
• Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisCompletedNCT01433497Phase 3
• Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)CompletedNCT01432704Phase 2/3
• A Phase IIa Study of NT-KO-003 for Multiple SclerosisCompletedNCT01428726Phase 2
• [18F]PBR111 and Microglial Activation in Multiple SclerosisTerminatedNCT01428505Phase 2
• NOGO-A in Multiple Sclerosis FTIHTerminatedNCT01424423Phase 1
• Fingolimod -Response According to Coping - EvaluationCompletedNCT01420055Phase 4
• Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)CompletedNCT01419301Not applicable
• Metabolic Effects of a Green Tea Extract in Multiple Sclerosis PatientsCompletedNCT01417312Not applicable
• Impact of Vitamin A on Multiple Sclerosis (MS)Status unknownNCT01417273Phase 4
• Betaferon® Regulatory Post-Marketing SurveillanceCompletedNCT01414816
• Core Stability Training in Multiple SclerosisCompletedNCT01414725Not applicable
• Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated SyndromeTerminatedNCT01413243Phase 2
• Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple SclerosisTerminatedNCT01411514Phase 4
• Impact of Vitamin A on Gene Expression, in Multiple Sclerosis PatientStatus unknownNCT01407211Phase 4
• Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis PatientsCompletedNCT01399957
• Environmental and Genetic Risk Factors for Pediatric Multiple SclerosisCompletedNCT01396343
• Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative DiseasesCompletedNCT01384825
• An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral SclerosisTerminatedNCT01384162Phase 1/2
• Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)CompletedNCT01381354Phase 1
• Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis PatientsTerminatedNCT01380041
• A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01378676Phase 2
• Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism InvestigationStatus unknownNCT01378026
• Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple SclerosisCompletedNCT01377870Phase 1/2
• Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in LifeWithdrawnNCT01377805
• Digital UlcerationCompletedNCT01377090
• BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)CompletedNCT01371760Not applicable
• Cohort Study of Clinically Isolated Syndrome and Early Multiple SclerosisStatus unknownNCT01371071
• Avonex PEN Satisfaction and Patients Experience Clinical TrialCompletedNCT01366040
• PRISM Registry: Pseudobulbar Affect Registry SeriesCompletedNCT01366027
• Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaStatus unknownNCT01364246Phase 1/2
• Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)TerminatedNCT01363882Not applicable
• Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisCompletedNCT01359566Phase 3
• Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)CompletedNCT01356134
• Depression and Fatigue in MS Patients Treated With Betaferon.CompletedNCT01354665
• Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral SclerosisStatus unknownNCT01348451Phase 1
• Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)Status unknownNCT01339676Phase 4
• Supported Treadmill Training for Progressive Multiple SclerosisCompletedNCT01339234Not applicable
• Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple SclerosisWithdrawnNCT01337427Phase 3
• Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis PatientsStatus unknownNCT01333358Phase 3
• Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisCompletedNCT01326715Phase 1
• A Study of ELND002 in Patients With Relapsing Forms of Multiple SclerosisTerminatedNCT01318421Phase 1
• Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01310166Phase 4
• Advanced MRI Measures of Repair in Alemtuzumab Treated PatientsCompletedNCT01307332Phase 3
• Cyclic Oral Methylprednisolone Trial in Multiple SclerosisCompletedNCT01305837Phase 2
• Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple SclerosisStatus unknownNCT01303770Not applicable
• Nurse-Led Manualized Telephone Support InterventionCompletedNCT01302431Not applicable
• Safety Extension Study of TRO19622 in ALSCompletedNCT01285583Phase 2/3
• The Gilenya Pregnancy RegistryCompletedNCT01285479
• Fresolimumab In Systemic SclerosisCompletedNCT01284322Phase 1

← Sclerosis overview